AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
AstraZeneca ( (GB:AZN) ) has provided an announcement.
AstraZeneca reported that, as of 30 June 2026, its issued share capital with voting rights stands at 1,551,024,534 ordinary shares, each with a nominal value of US$0.25, and that no shares are held in Treasury. This figure, which represents the company’s total voting rights, serves as the reference denominator for shareholders in determining whether they must disclose new or altered holdings under U.K. Financial Conduct Authority transparency rules.
The clarified voting-rights base enhances transparency for investors by confirming there has been no dilution from Treasury holdings and by standardising the metric used for regulatory disclosure thresholds. This update supports orderly market oversight and provides institutional and retail shareholders with a clear basis for monitoring ownership changes and compliance with disclosure obligations in AstraZeneca’s listed securities.
The most recent analyst rating on (GB:AZN) stock is a Buy
with a £16500.00 price target.
To see the full list of analyst forecasts on AstraZeneca stock,
see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying fundamentals (profitability, margins, and returns) and a constructive earnings update with reiterated guidance and meaningful pipeline progress. These positives are partly offset by weak technical momentum, moderate valuation, and near-term cash/debt pressures tied to higher investment and payments.
To see Spark’s full report on AZN stock,
click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, U.K., focused on discovering, developing and commercialising prescription medicines. Its core therapeutic areas include Oncology, Rare Disease and BioPharmaceuticals, spanning Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries to millions of patients worldwide.
Average Trading Volume: 2,154,421
Technical Sentiment Signal: Strong Buy
Current Market Cap: £218.7B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
